View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Mar. 31, 2013	May 05, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Biota Pharmaceuticals, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		28,423,990
Amendment Flag	false
Entity Central Index Key	0000072444
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2013	Jun. 30, 2012
Current assets
Cash and cash equivalents	$ 70,265	$ 53,790
Accounts receivable	15,173	5,966
Prepaid and other current assets	1,847	1,374
Total current assets	87,285	61,130
Non-current assets:
Property and equipment, net	4,173	4,944
Intangible assets, net	818	1,804
Deferred tax assets	2,563	1,419
Total non-current assets	7,554	8,167
Total assets	94,839	69,297
Current liabilities:
Accounts payable	2,282	2,851
Accrued expenses	5,935	6,133
Accrued severance obligations	3,858	0
Deferred revenue	650	398
Deferred tax liabilities	1,714	130
Total current liabilities	14,439	9,512
Non-current liabilities:
Other liabilities, net of current portion	296	504
Total non-current liabilities	296	504
Total liabilities	14,735	10,016
Stockholders’ equity:
Common stock, $0.10 par value; 200,000,000 shares authorized 34,219,690 shares issued and 182,350,316 shares outstanding at March 31, 2013 and June 30, 2012, respectively	3,422	100,394
Additional paid-in capital	234,775	668
Treasury stock, 5,867,361 and 1,816,178 at cost, at March 31, 2013 and June 30, 2012, respectively	(117,048)	(1,397)
Accumulated other comprehensive income	31,053	29,516
Accumulated deficit	(72,098)	(69,900)
Total stockholders’ equity	80,104	59,281
Total liabilities and stockholders’ equity	$ 94,839	$ 69,297

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2013	Jun. 30, 2012
Common Stock, Par value (in Dollars per share) (in Dollars per share)	$ 0.10	$ 0.10
Shares Authorized (in Shares)	200,000,000	200,000,000
Shares Issued (in Shares)	34,219,690	182,350,316
Common stock, shares outstanding (in Shares)	34,219,690	182,350,316
Treasury stock, shares, at cost (in Shares)	5,867,361	1,816,178

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Revenue:
Royalty revenue and milestones	$ 7,709	$ 5,189	$ 9,636	$ 6,649
Revenue from services	4,787	1,879	14,468	6,611
Other		22	242	69
Total revenue	12,496	7,090	24,346	13,329
Operating expense:
Cost of revenue	4,094	1,787	12,731	6,047
Research and development	4,936	5,713	13,583	17,769
General and administrative	3,436	2,220	13,704	5,871
Total operating expense	12,466	9,720	40,018	29,687
Income/(loss) from operations	30	(2,630)	(15,672)	(16,358)
Non-operating income:
Gain recorded on merger	0	0	7,805	0
Research and development credit	0	0	4,428	0
Interest income	173	739	1,125	2,565
Total non-operating income	173	739	12,358	2,565
Income (loss) before tax	203	(1,891)	(2,314)	(13,793)
Income tax benefit/(expense)	12	(146)	116	504
Net Income (Loss)	$ 215	$ (2,037)	$ (2,198)	$ (13,289)
Basic income (loss) per share (in Dollars per share)	$ 0.01	$ (0.09)	$ (0.08)	$ (0.59)
Diluted income (loss) per share (in Dollars per share)	$ 0.01	$ (0.09)	$ (0.08)	$ (0.59)
Basic weighted-average shares outstanding (in Shares)	28,162,295	22,709,008	28,145,541	22,709,008
Diluted weighted-average shares outstanding (in Shares)	28,182,697	22,709,008	28,145,541	22,709,008
Comprehensive income (loss):
Exchange differences on translation of foreign operations, net of tax	$ 536	$ 1,610	$ 1,537	$ (1,456)
Total comprehensive income (loss)	$ 751	$ (427)	$ (661)	$ (14,745)

Condensed Statements of Stockholders’ Equity (Unaudited) - 9 months ended Mar. 31, 2013 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Translation Adjustment [Member]	Total
Balances at July 1, 2012 at Jun. 30, 2012	$ 100,394	$ 668	$ (1,397)	$ (69,900)	$ 29,516	$ 59,281
Balances at July 1, 2012 (in Shares) at Jun. 30, 2012	182,350,316		(1,816,178)			182,350,316
Balances at March 31, 2013 at Mar. 31, 2013	$ 3,422	234,775	$ (117,048)	(72,098)	31,053	$ 80,104
Balances at March 31, 2013 (in Shares) at Mar. 31, 2013	34,219,690		(5,867,361)			34,219,690
Comprehensive income
Exchange differences on translation of foreign operations					$ 1,537	$ 1,537
Net loss				$ (2,198)		(2,198)
Total Comprehensive income						(661)
New shares issued on exercise of options	$ 410	(410)
New shares issued on exercise of options (in Shares)	413,335
New shares issued on vesting of options on merger	$ 1,118	(1,118)
Acquisition of Nabi Biopharmaceuticals (in Shares)	(153,398,048)		(4,051,183)
Restricted stock units, net	$ 21	(21)
Restricted stock units, net (in Shares)	214,983
Share-based compensation		2,289				2,289
New shares issued on vesting of options on merger (in Shares)	4,639,104
Acquisition of Nabi Biopharmaceuticals	$ (98,521)	$ 233,367	$ (115,651)			$ 19,195

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (2,198)	$ (13,289)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,447	2,463
Share-based compensation	2,289	424
Gain recorded on merger	(7,805)	0
Change in operating assets and liabilities (net of liabilities acquired):
Accounts receivables	(8,667)	(5,462)
Prepaid expenses and other current assets	(445)	(360)
Deferred tax assets	414	(504)
Deferred revenue	237	255
Accounts payable and accrued expenses	(1,607)	(1,993)
Accrued severance obligations	(1,032)	0
Net cash used in operating activities	(16,367)	(18,466)
Cash flows from investing activities:
Cash acquired on merger	32,687
Purchases of property and equipment	(490)	(1,062)
Proceeds from sale of property and equipment		8
Net cash provided by (used in) investing activities	32,197	(1,054)
Increase (decrease) in cash and cash equivalents	15,830	(19,520)
Cash and cash equivalent at beginning of period	53,790	74,177
Effects of exchange rate movements on cash and cash equivalents	645	(1,319)
Cash and cash equivalents at end of period	70,265	53,338
Supplemental cash flow disclosure:
Proceeds from the issuance of common stock on merger	27,000
Proceeds to settle accrued severance obligations and other accrued liabilities on merger	$ 5,687	$ 0

Note 1 - Company Overview

9 Months Ended

Mar. 31, 2013

Nature of Operations [Text Block]

(1) Company Overview

Biota Pharmaceuticals, Inc., together with its wholly owned subsidiaries (“Biota”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of innovative anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases. The Company has been incorporated in the state of Delaware since 1969 and the corporate headquarters are located in Alpharetta, Georgia. On November 8, 2012, Nabi Biopharmaceuticals (“Nabi”) merged with Biota Holdings Limited and the resulting company was renamed Biota Pharmaceuticals, Inc.

The Company is currently focused on developing oral, small molecule compounds to treat a number of infections, with its clinical-stage programs being directed toward respiratory diseases, including those caused by influenza A and B, and human rhinovirus (“HRV”). In addition, it has preclinical research programs directed toward developing products to treat respiratory syncytial virus (“RSV”) as well as a broad spectrum of gram negative bacterial infections.

The Company has developed a neuraminidase inhibitor, zanamivir, which is marketed worldwide by GlaxoSmithKline (“GSK”) as Relenza™ for the prevention and treatment of influenza pursuant to a research and license agreement entered into with the Company in 1990. In addition, the Company has cross-licensed intellectual property related to second-generation long-acting neuraminidase inhibitors (“LANI”) with Daiichi Sankyo Company Ltd (“Daiichi Sankyo”), of which the lead product, laninamivir octanoate, was developed and is being marketed by Daiichi Sankyo as lnavir® Dry Powder Inhaler (“Inavir®”) in Japan for the treatment of influenza A & B infections. The Company has filed an Investigational New Drug application (“IND”) with the United States Food and Drug Administration (“FDA”) to develop laninamivir octanoate, and in 2011 entered into a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (“BARDA”) designed to provide up to $231 million for the completion of clinical development and United States (“U.S.”) based manufacturing of laninamivir octanoate for the treatment of influenza A and B infections.

Although the Company’s influenza products have been successfully commercialized by other larger pharmaceutical companies under license agreements, the Company has not received regulatory approval for any product candidates it has developed independently, and does not have any commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any of its existing or future product candidates.

Note 2 - Basis of Presentation

9 Months Ended

Mar. 31, 2013

Basis of Presentation and Significant Accounting Policies [Text Block]

(2) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of the Company’s management, all material adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Certain information and footnotes disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements included in our Form 8-K/A filed on January 23, 2013.

The unaudited interim consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation.

Operating results for the nine months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending June 30, 2013.

For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the year ended June 30, 2012 included in the Company’s Current Report filed on Form 8-K/A that was filed with the SEC on January 23, 2013.

The Company’s significant accounting policies have not changed since December 31, 2012, except as outlined below:

Recent Accounting Standards

In February 2013, the Financial Accounting Standards Board (“FASB”) issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income. Adoption of the new guidance did not have an impact on the Company’s consolidated financial statements.

In March 2013, FASB issued ASU 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (a consensus of the FASB Emerging Issues Task Force), effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company does not expect adoption will have a material impact on its consolidated financial statements.

Note 3 - Merger

9 Months Ended

Mar. 31, 2013

Business Combination Disclosure [Text Block]

(3) Merger

Reverse Stock Split

On November 8, 2012, in connection with the merger - described below and as approved by Nabi’s stockholders and board of directors, Nabi filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to affect a reverse stock split of Nabi’s common stock at a ratio of 1:6. As a result of the reverse stock split, each six shares of Nabi common stock issued and outstanding immediately prior to the reverse stock split were automatically combined into and became one share of Nabi common stock. Also, as a result of the reverse stock split, the per share exercise price of, and the number of shares of common stock underlying, the Company outstanding stock options immediately prior to the reverse stock split were automatically proportionally adjusted based on the one-for-six split ratio in accordance with the terms of such options. The reverse stock split did not alter the par value or modify any voting rights or other terms of the common stock.

Merger between Nabi Biopharmaceuticals and Biota Holdings Limited

On November 8, 2012, Nabi and Biota Holdings Limited completed a merger (the “Merger”), and the resulting company was renamed Biota Pharmaceuticals, Inc. Former Biota Holdings Limited shareholders retained approximately 83% of the Company’s shares of common stock, while former Nabi shareholders retained approximately 17% as consideration for Nabi’s net assets, the vast majority of which was $27 million in net cash on hand on the date of the merger. As Nabi had minimal ongoing activity with respect to its development programs and related operations at the time of the merger, the Company’s future operations will be largely represented by the operations of Biota Holdings Limited. Further, due to the fact that former Biota Holdings Limited shareholders held a significant majority of the voting interest in the Company upon the completion of the merger, the merger has been accounted for as a “reverse merger”, such that, notwithstanding the fact that Nabi was the legal acquirer, Biota Holdings Limited is considered the accounting acquirer for financial reporting purposes. Accordingly, the financial statements of Biota Holdings Limited are treated as the historical financial statements of the Company, with the operating results of Nabi being included from November 8, 2012. As a result of the reverse merger, historical common stock amounts and additional paid-in capital have been adjusted.

Exchange Ratio

Upon completion of the merger, each outstanding share of Biota Holdings Limited common stock converted into the right to receive 0.1249539870 shares of Nabi common stock as determined by the exchange ratio - as calculated pursuant to the terms of the merger, as amended. Pursuant to the various agreements, Biota Holdings Limited stockholders received shares of Nabi common stock representing approximately 83% of the outstanding combined shares of the resulting combined company. Nabi stockholders continued to own their shares of existing Nabi common stock, which represented approximately 17% of the outstanding combined shares of the resulting combined company. The issued share capital upon completion of the merger was comprised of the following:

	No. of Shares
Ex-Nabi stockholders		4,720,999
Ex-Biota Holdings Limited stockholders		23,416,347
Total		28,137,346

Purchase Consideration and Net Assets Acquired

The purchase consideration in a reverse merger is determined with reference to the value of equity that the accounting acquirer (in this case Biota Holdings Limited,) issues to the stockholders of the accounting acquiree (Nabi, in this case) to give them their interest in the combined entity. Further, as a result of the merger, stock options to purchase an aggregate of 0.5 million shares of Nabi common stock that were held by officers and directors of Nabi immediately vested. The fair values of Nabi’s outstanding stock options were determined using the Black-Scholes option pricing model with the following assumptions: a strike price range of $11.34 – $99.91; a volatility range between 78.79% – 99.62%; a risk-free interest rate range of 0.12% – 0.87%; and an expected life range of 0.3 – 6.1 years.

The purchase price, based on the price per share of the Company’s common stock as of the date of the merger is as follows:

Number of shares issued to Nabi stockholders			4,720,999
Fair value per share, using the volume weighted share price on November 9, 2012			$4.0168
Implied purchase consideration (in thousands)			$18,963

Number of stock options outstanding to former Nabi employees and directors			508,918
Fair value per option			$0.456
Implied purchase consideration (in thousands)			$232

Total implied purchase consideration (in thousands)			$19,195

The net assets acquired as a result of the merger consist of (in thousands):

Cash	$32,687
Accrual for severance obligations and employee benefits	(4,977	)
Accounts payable	(694	)
Other liabilities	(16	)
Net cash received	$27,000

Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	$7,805

Due to the significant uncertainty associated with future cash flows from these assets, no purchase consideration has been allocated to the residual value of any of Nabi’s drug development programs, including NicVAX® or any next-generation nicotine vaccine, or the potential royalty of Phoslyra that was sold to a third party in 2006.

Pursuant to the merger, Biota Holdings Limited received net cash of $27 million from Nabi, while Nabi stockholders received a proportion of the combined entity based on the Biota Holdings Limited share price upon completion of the merger. Movements in the Biota Holdings Limited share price and the U.S. and Australian dollar exchange rates between the date of the determination of the exchange ratio and the date of the completion of the merger, coupled with changes in the fair value of certain assets and liabilities, resulted in the net assets acquired exceeding the calculated purchase consideration. The resulting gain of $7.8 million recorded on the completion of the merger is recognized as non-operating income in the condensed consolidated statements of operations.

Acquisition-related Costs

Acquisition-related costs associated with the merger, including advisory, investment banking, legal, accounting and various other costs of Nil and $4.6 million have been included as a general and administrative expense for the three and nine month periods ended March 31, 2013, respectively. Total acquisition-related costs were approximately $6.5 million.

Pro forma Financial Information

The following table presents selected unaudited financial information, as if the merger with Nabi had occurred on July 1, 2011 (in thousands, expect per share data).

	Three Months Ended March 31,						Nine Months Ended March 31,
	2013			2012			2013			2012

Pro forma net revenue		$13,128			$7,722			$25,610			$8,792
Pro forma net loss		$(3,986	)		$(2,473	)		$(8,931	)		$(13,600	)
Pro forma basic loss per share		$(0.14	)		$(0.11	)		$(0.32	)		$(0.60	)
Pro forma diluted loss per share		$(0.14	)		$(0.11	)		$(0.32	)		$(0.60	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 4 - Net Income (Loss) Per Share

9 Months Ended

Mar. 31, 2013

Earnings Per Share [Text Block]

(4) Net Income (Loss) per Share

Basic and diluted income (loss) per share has been computed based on net income (loss) and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and warrants) are excluded from the calculation of diluted net loss per share as their inclusion would be anti-dilutive. The Company has excluded all options to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following table sets forth the computation of historical basic and diluted net income (loss) per share.

	Three Months Ended March 31,					Nine Months Ended March 31,
	2013		2012			2013			2012

Net income (loss) (in thousands)		$215		$(2,037	)		$(2,198	)		$(13,289	)
Weighted-average shares outstanding		28,165,295		181,664,389			28,145,541			181,664,389
Weighted- average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-		22,709,008			-			22,709,008
Dilutive effect of restricted stock and stock options		20,402		-			-			-
Shares used to compute diluted earnings per share		28,182,697		22,709,008			28,145,541			22,709,008
Basic income (loss) per share		$0.01		$(0.09	)		$(0.08	)		$(0.59	)
Diluted income (loss) per share		$0.01		$(0.09	)		$(0.08	)		$(0.59	)

Note 5 - Share Based Compensation

9 Months Ended

Mar. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(5) Share-Based Compensation

A summary of stock option grants outstanding as of March 31, 2013, and the related activity during the nine months ended March 31, 2013, is presented below:

	Number of Options
Options	Biota Holdings Limited			Nabi			Biota Pharmaceuticals, Inc.

Outstanding at June 30, 2012		6,182,853			3,665,201
Granted		686,365			-
Exercised		(413,335	)		-
Forfeited		-			(20,000	)
Expired		(601	)		(591,485	)

		6,455,282			3,053,716
Adjustment for consolidation of shares (reverse stock split)					(2,544,716	)
Vested and exercised upon merger		(6,455,282	)		-
Balance on November 8, 2012 (date of merger)		-			508,918

Post-merger transactions:
Granted		-			-			931,590
Expired		-			(16,979	)		-

Outstanding at March 31, 2013		-			491,939			931,590

Exercisable at March 31, 2013		-			491,939			-

On November 8, 2012, and in connection with the merger and based upon stockholder approval, Nabi’s board of directors approved a 1:6 reverse stock split of existing Nabi shares, which reduced the number of shares of common stock reserved for outstanding stock options to 508,918. The exercise price of all outstanding stock options as of that date have been adjusted to reflect the reverse stock split and are now between $11.22 and $99.94 per share, with terms expiring from March, 2014 to January, 2019.

Biota Holdings Limited had outstanding stock options to purchase 6,455,282 shares of its common stock at September 30, 2012. Upon approval of the merger with Nabi by the Supreme Court of Victoria on October 26, 2012, all of these outstanding stock options vested, resulting in the issuance of 4,639,104 shares of common stock and the vesting of 1,816,178 shares held by Biota Holdings Limited for this purpose. The related expense of $1.1 million associated with the issuance of shares of common stock has been recognized as a general and administrative expense in the consolidated statement of operations of Biota Holdings Limited.

On November 12, 2012, the Company granted options to purchase 931,590 shares of common stock at an exercise price of $4.07. The grant becomes exercisable in three equal installments on the first, second and third anniversary of the grant date. The options have a 10 year term. The Company estimated the fair value of each stock option on the date of grant, using the Black-Scholes option-pricing formula, to be $2.72 using the following key assumptions:

Expected Term: The expected term represents the period over which the share-based awards are expected to be outstanding based on the Company’s historical experience. The Company estimated an expected term of 5 years.

Risk-Free Interest Rate: The Company used a risk-free rate of 0.65%, based upon the risk-free interest rate used in the assumptions on the implied yield currently available on the U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock option award.

Expected volatility: The Company used an expected volatility factor of 83.84%, based on the historical price of its common stock over the most recent period commensurate with the expected term of the stock option award.

Expected Dividend Yield: The Company does not intend to pay any cash dividends on common stock for the foreseeable future. Accordingly, it assumed a dividend yield of zero.

The Company amortizes share-based compensation expense over the option’s vesting period using the straight-line attribution approach. For the three and nine month periods ended March 31, 2013, the Company recognized approximately $0.1 million and $0.3 million respectively of share-based compensation expense related to the issuance of stock option grants.

A summary of outstanding restricted stock awards as of March 31, 2013, and the related activity during the nine month period ending March 31, 2013 is presented below:

	Number of Awards
Awards	Nabi			Biota Pharmaceuticals, Inc.

Unvested at June 30, 2012		196,254
Vested and shares issued		(196,254	)

Balance on November 8, 2012 (date of merger)		-

Post-merger transactions:
Granted		-			214,983
Vested		-			(71,661	)

Outstanding at March 31, 2013	Nil				143,322

On November 12, 2012, the Company granted 214,983 of restricted stock awards with an average fair value of $4.07. The restricted shares vest over three equal installments: upon 90 days, and on the first and second anniversaries of the grant date. For the three month and nine month periods ended March 31, 2013, the Company recognized approximately $0.2 million and $0.3 million of share-based compensation expense related to the issuance of restricted stock units.

As of March 31, 2013, there was $2.7 million of unrecognized compensation expense related to unvested share-based compensation arrangements. This expense is expected to be recognized over the next two years as the shares vest.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 6 - Research and Development Credit

9 Months Ended

Mar. 31, 2013

Research, Development, and Computer Software Disclosure [Text Block]

(6) Research and Development Credit

An application for a claim of $4.4 million was made by the Company’s subsidiary, Biota Holdings Limited, under the Australian Government’s Research and Development tax incentive when Biota Holdings Limited submitted its tax return for its fiscal year ended June 30, 2012. This amount was recorded as a contingent asset as of June 30, 2012. On November 7, 2012, Biota Holdings Limited received cash for this claim. Although the credit is administered by the Australian government, it is not linked to the level of taxable income and is effectively a government grant. As such, the Company obtained an immediate benefit and therefore, the entire amount has been recognized within non-operating income in the consolidated statement of operations for the nine month period ending March 31, 2013.

For the current fiscal year, the Company does not expect to receive a research and development credit as its revenue is expected to exceed the qualifying revenue threshold.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Audit and Accounting Guide (AAG)
-Number AAG-FGC
-Paragraph 56, 57
-IssueDate 2006-05-01
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 68
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 7 - Licences, Royalty Collaborative and Contractual Arrangements

9 Months Ended

Mar. 31, 2013

Collaborative Arrangement Disclosure [Text Block]

(7) Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with GSK in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor (“NI”) marketed by GSK as RelenzaTM to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and is entitled to receive royalty payments of 7% of GSK's annual net sales of RelenzaTM in the U.S., Europe, Japan and certain other countries as well as 10% of GSK's annual net sales of RelenzaTM in Australia, New Zealand, South Africa and Indonesia. Beginning in 2014, the patents on RelenzaTM are scheduled to expire in certain countries and are scheduled to fully expire in 2019.

The Company also generates royalty revenue from the net sales of Inavir® in Japan, pursuant to a collaboration and license agreement that the Company entered into with Daiichi Sankyo in 2009 related to the development and commercialization of second generation, LANI, including laninamivir octanoate. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza, which Daiichi Sankyo markets as Inavir®. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir® in Japan and is eligible to earn commercial milestone payments. Under the collaboration and license agreement, the Company and Daiichi Sankyo have cross-licensed the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan. Patents on laninamivir octanoate in Japan generally expire in 2024.

Collaborative and contract arrangements

On March 31, 2011, the Company’s wholly owned subsidiary, Biota Scientific Management Pty Ltd., was awarded a contract by BARDA for the late-stage development of laninamivir octanoate on a cost-plus-fixed-fee basis, the total of which is not to exceed $231.2 million. BARDA is part of the U.S. Office of the Assistant Secretary for Preparedness and Response ("ASPR") within the U.S. Department of Health and Human Services ("HHS"). The BARDA contract is designed to fund and provide the Company with all technical and clinical data, and to establish U.S. based manufacturing, to support the filing of a U.S. new drug application (“NDA”) with the FDA for laninamivr octanoate. The performance period of the BARDA contract commenced on March 31, 2011, and continues for five years.

The Company is considered an active participant in the BARDA contract, with exposure to significant risks and rewards of commercialization relating to the development of laninamivir octanoate. Therefore, revenues from and costs associated with the contract are recorded and recognized on a gross basis in the consolidated statement of operations. Revenue totaling $22.5 million has been recognized to-date pursuant to this contract.

The following tables summarize the key components of the Company’s revenues for the three month and nine month periods ended March 31, 2013 and 2012:

	Three Months Ended March 31,
	2013		2012
	(in millions)
Royalty revenue – RelenzaTM		$1.7		$1.7
– Inavir®		3.2		3.6
Commercial milestone – Inavir®		2.9		-
Service revenue under BARDA contract		4.5		1.7
Revenue under other contracts, grants and collaborations		0.2		0.1
Total revenue		$12.5		$7.1

	Nine Months Ended March 31,
	2013		2012
	(in millions)
Royalty revenue – RelenzaTM		$2.7		$2.4
– Inavir®		4.1		4.3
Commercial milestone – Inavir®		2.9		-
Service revenue under BARDA contract		13.7		6.2
Revenue under other contracts, grants and collaborations		1.0		0.4
Total revenue		$24.4		$13.3

Note 8 - Subsequent Events

9 Months Ended

Mar. 31, 2013

Subsequent Events [Text Block]

(8) Subsequent Event

On April 15, 2013, the Company announced that its Board of Directors has adopted a revised corporate strategy following the recent completion of management’s strategic and operational review of the organization and its various development programs. The implementation of this strategy will shift the Company’s primary strategic and operational focus from early-stage research to clinical-stage development programs. As a result of adopting this strategy, the Company has rationalized its preclinical programs, realigned its resources, and reduced its workforce by approximately 30%.

Accordingly, the Company anticipates recording a charge of approximately $2.0 million in the fourth quarter of its 2013 fiscal year (the Company’s fiscal year-end is June 30) related to the cost of one-time termination benefits.

On May 1, 2013 the Board of Directors retired 5,867,361 shares of the Company's treasury stock.

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Mar. 31, 2013
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of the Company’s management, all material adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Certain information and footnotes disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements included in our Form 8-K/A filed on January 23, 2013. The unaudited interim consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation. Operating results for the nine months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending June 30, 2013. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the year ended June 30, 2012 included in the Company’s Current Report filed on Form 8-K/A that was filed with the SEC on January 23, 2013. The Company’s significant accounting policies have not changed since December 31, 2012, except as outlined below:
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards In February 2013, the Financial Accounting Standards Board (“FASB”) issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income. Adoption of the new guidance did not have an impact on the Company’s consolidated financial statements. In March 2013, FASB issued ASU 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (a consensus of the FASB Emerging Issues Task Force), effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company does not expect adoption will have a material impact on its consolidated financial statements.

Note 3 - Merger (Tables)

9 Months Ended

Mar. 31, 2013

Schedule of Stockholders Equity [Table Text Block]

	No. of Shares
Ex-Nabi stockholders		4,720,999
Ex-Biota Holdings Limited stockholders		23,416,347
Total		28,137,346

Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]

Number of shares issued to Nabi stockholders			4,720,999
Fair value per share, using the volume weighted share price on November 9, 2012			$4.0168
Implied purchase consideration (in thousands)			$18,963

Number of stock options outstanding to former Nabi employees and directors			508,918
Fair value per option			$0.456
Implied purchase consideration (in thousands)			$232

Total implied purchase consideration (in thousands)			$19,195

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Cash	$32,687
Accrual for severance obligations and employee benefits	(4,977	)
Accounts payable	(694	)
Other liabilities	(16	)
Net cash received	$27,000

Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger	$7,805

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended March 31,						Nine Months Ended March 31,
	2013			2012			2013			2012

Pro forma net revenue		$13,128			$7,722			$25,610			$8,792
Pro forma net loss		$(3,986	)		$(2,473	)		$(8,931	)		$(13,600	)
Pro forma basic loss per share		$(0.14	)		$(0.11	)		$(0.32	)		$(0.60	)
Pro forma diluted loss per share		$(0.14	)		$(0.11	)		$(0.32	)		$(0.60	)

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References + Details

Note 4 - Net Income (Loss) Per Share (Tables)

9 Months Ended

Mar. 31, 2013

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31,					Nine Months Ended March 31,
	2013		2012			2013			2012

Net income (loss) (in thousands)		$215		$(2,037	)		$(2,198	)		$(13,289	)
Weighted-average shares outstanding		28,165,295		181,664,389			28,145,541			181,664,389
Weighted- average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-		22,709,008			-			22,709,008
Dilutive effect of restricted stock and stock options		20,402		-			-			-
Shares used to compute diluted earnings per share		28,182,697		22,709,008			28,145,541			22,709,008
Basic income (loss) per share		$0.01		$(0.09	)		$(0.08	)		$(0.59	)
Diluted income (loss) per share		$0.01		$(0.09	)		$(0.08	)		$(0.59	)

Note 5 - Share Based Compensation (Tables)

9 Months Ended

Mar. 31, 2013

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Options
Options	Biota Holdings Limited			Nabi			Biota Pharmaceuticals, Inc.

Outstanding at June 30, 2012		6,182,853			3,665,201
Granted		686,365			-
Exercised		(413,335	)		-
Forfeited		-			(20,000	)
Expired		(601	)		(591,485	)

		6,455,282			3,053,716
Adjustment for consolidation of shares (reverse stock split)					(2,544,716	)
Vested and exercised upon merger		(6,455,282	)		-
Balance on November 8, 2012 (date of merger)		-			508,918

Post-merger transactions:
Granted		-			-			931,590
Expired		-			(16,979	)		-

Outstanding at March 31, 2013		-			491,939			931,590

Exercisable at March 31, 2013		-			491,939			-

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

	Number of Awards
Awards	Nabi			Biota Pharmaceuticals, Inc.

Unvested at June 30, 2012		196,254
Vested and shares issued		(196,254	)

Balance on November 8, 2012 (date of merger)		-

Post-merger transactions:
Granted		-			214,983
Vested		-			(71,661	)

Outstanding at March 31, 2013	Nil				143,322

Note 7 - Licences, Royalty Collaborative and Contractual Arrangements (Tables)

9 Months Ended

Mar. 31, 2013

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended March 31,
	2013		2012
	(in millions)
Royalty revenue – RelenzaTM		$1.7		$1.7
– Inavir®		3.2		3.6
Commercial milestone – Inavir®		2.9		-
Service revenue under BARDA contract		4.5		1.7
Revenue under other contracts, grants and collaborations		0.2		0.1
Total revenue		$12.5		$7.1

	Nine Months Ended March 31,
	2013		2012
	(in millions)
Royalty revenue – RelenzaTM		$2.7		$2.4
– Inavir®		4.1		4.3
Commercial milestone – Inavir®		2.9		-
Service revenue under BARDA contract		13.7		6.2
Revenue under other contracts, grants and collaborations		1.0		0.4
Total revenue		$24.4		$13.3

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Note 1 - Company Overview (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
Note 1 - Company Overview (Detail) - USD ($) $ in Millions	Mar. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012	Jun. 30, 2011
BARDA
Contracts Revenue (in Dollars)						$ 231.0
Contracts Revenue (in Dollars)	$ 231.2	$ 0.2	$ 0.1	$ 1.0	$ 0.4

Note 3 - Merger (Detail) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Nov. 08, 2012	Mar. 31, 2013
General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs (in Dollars)		$ 4.6
Minimum [Member] \| Nabi
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price (in Dollars per share)		$ 11.34
Fair Value Assumptions, Expected Volatility Rate	78.79%
Fair Value Assumptions, Risk Free Interest Rate	0.12%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term	109 days
Maximum [Member] \| Nabi
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price (in Dollars per share)		$ 99.91
Fair Value Assumptions, Expected Volatility Rate	99.62%
Fair Value Assumptions, Risk Free Interest Rate	0.87%
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term	6 years 36 days
Biota Holdings Limited
Ownership Percentage	83.00%
Business Acquisition, Percentage of Voting Interests Acquired	83.00%
Nabi
Ownership Percentage	17.00%
Business Acquisition, Percentage of Voting Interests Acquired	17.00%
Stockholders' Equity, Reverse Stock Split	1:6
Net closing cash balance (in Dollars)	$ 27.0
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)	0.1249539870
Cash Acquired from Acquisition, Net (in Dollars)	$ 27.0
Business Combination, Bargain Purchase, Gain Recognized, Amount (in Dollars)	$ 7.8
Business Combination, Acquisition Related Costs (in Dollars)		$ 6.5

Note 3 - Merger (Detail) - Issued Share Capital	Mar. 31, 2013 shares
Nabi
Number of Shares on Issue	4,720,999
Biota Holdings Limited
Number of Shares on Issue	23,416,347
Number of Shares on Issue	28,137,346

Note 3 - Merger (Detail) - Fair Value Purchase Consideration - Nabi $ / shares in Units, $ in Thousands	9 Months Ended
	Mar. 31, 2013 USD ($) $ / shares shares
Stock Options [Member]
Fair Value Purchase Consideration	$ 232
Stock Shares
Fair Value Purchase Consideration	$ 18,963
Number of shares issued to Nabi stockholders (in Shares) \| shares	4,720,999
Fair value per share, using the volume weighted share price on November 9, 2012 (in Dollars per share) \| $ / shares	$ 4.0168
Fair Value Purchase Consideration	$ 19,195
Number of stock options outstanding to former Nabi employees and directors (in Shares) \| shares	508,918
Fair value per option (in Dollars per share) \| $ / shares	$ 0.456

- Definition

Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910684&loc=d3e4570-128470

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4237-128469

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4243-128469

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 40
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910732&loc=d3e4805-128471

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3642-128468

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 27
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3629-128468

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(3),(c)(1)
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 3 - Merger (Detail) - Net Assets Acquired - USD ($) $ in Thousands		6 Months Ended	9 Months Ended
	Nov. 08, 2012	Dec. 31, 2012	Mar. 31, 2013
Biota
Cash		$ 32,687
Accrual for severance obligations and employee benefits		(4,977)
Accounts payable		(694)
Other liabilities		(16)
Net cash received		27,000
Excess of net assets acquired over total fair value purchase consideration/gain recorded on merger		$ 7,805
Cash			$ 32,687
Net cash received	$ 27,000

Note 3 - Merger (Detail) - Business Acquisition Pro Forma Information - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Pro forma net revenue (in Dollars)	$ 13,128	$ 7,722	$ 25,610	$ 8,792
Pro forma net loss (in Dollars)	$ (3,986)	$ (2,473)	$ (8,931)	$ (13,600)
Pro forma basic loss per share	$ (0.14)	$ (0.11)	$ (0.32)	$ (0.60)
Pro forma diluted loss per share	$ (0.14)	$ (0.11)	$ (0.32)	$ (0.60)

- Definition

The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

+ References + Details

- Definition

The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

+ References + Details

Note 4 - Net Income (Loss) Per Share (Detail) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Prior to Adjustments [Member]
Weighted average shares outstanding	28,165,295	181,664,389	28,145,541	181,664,389
Adjusted Using Exchange Ratio [Member]
Weighted average shares outstanding		22,709,008		22,709,008
Basic income (loss) per share (in Dollars per share)	$ 0.01	$ (0.09)	$ (0.08)	$ (0.59)
Diluted income (loss) per share (in Dollars per share)	$ 0.01	$ (0.09)	$ (0.08)	$ (0.59)
Earnings Per Share, Diluted [Member]
Shares used to compute diluted earnings per share	28,182,697	22,709,008	28,145,541	22,709,008
Net income (loss) (in thousands) (in Dollars)	$ 215	$ (2,037)	$ (2,198)	$ (13,289)
Weighted average shares outstanding	28,162,295	22,709,008	28,145,541	22,709,008
Dilutive effect of restricted stock and stock options	20,402
Shares used to compute diluted earnings per share	28,182,697	22,709,008	28,145,541	22,709,008
Basic income (loss) per share (in Dollars per share)	$ 0.01	$ (0.09)	$ (0.08)	$ (0.59)
Diluted income (loss) per share (in Dollars per share)	$ 0.01	$ (0.09)	$ (0.08)	$ (0.59)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 5 - Share Based Compensation (Detail) - USD ($)			1 Months Ended		3 Months Ended		9 Months Ended
Note 5 - Share Based Compensation (Detail) - USD ($)	Nov. 12, 2012	Nov. 08, 2012	Oct. 26, 2012	Sep. 30, 2012	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012	Jun. 30, 2012
Stock Options [Member]
Allocated Share-based Compensation Expense					$ 100,000		$ 300,000
Restricted Stock [Member]
Allocated Share-based Compensation Expense					$ 200,000		$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares)	214,983
Common Stock [Member]
Common Stock, Shares, Issued (in Shares)					34,219,690		34,219,690		182,350,316
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)			1,816,178		4,639,104		4,639,104
General and Administrative Expense			$ 1,100,000
Two Year Amortization Period [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized					$ 2,700,000		$ 2,700,000
Minimum [Member] \| Nabi
Investment Options, Exercise Price (in Dollars per share)		$ 11.22
Maximum [Member] \| Nabi
Investment Options, Exercise Price (in Dollars per share)		$ 99.94
Pre Merger
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)		508,918
Biota
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	931,590			6,455,282
Investment Options, Exercise Price (in Dollars per share)	$ 4.07
Estimate of Fair Value, Fair Value Disclosure [Member]
Share Price (in Dollars per share)	$ 2.72
Common Stock, Shares, Issued (in Shares)			4,639,104		34,219,690		34,219,690		182,350,316
General and Administrative Expense					$ 3,436,000	$ 2,220,000	$ 13,704,000	$ 5,871,000
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.65%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	83.84%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Restricted Investments, at Fair Value	$ 4.07
Share-Based Compensation Restricted Stock Number of Installments	3
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							90 days

Note 5 - Share Based Compensation (Detail) - Summary of Option Activity Under Stock Compensation Plans - shares	4 Months Ended	5 Months Ended
	Nov. 08, 2012	Mar. 31, 2013	Jun. 30, 2012
Biota Holdings Limited \| Pre Merger
Balance Outstanding	6,455,282
Post-merger transactions:
Granted	686,365
Expired	(601)
Biota Holdings Limited
Balance Outstanding			6,182,853
Post-merger transactions:
Vested and exercised upon merger	(6,455,282)
Exercised	(413,335)
Nabi \| Pre Merger
Balance Outstanding	3,053,716
Post-merger transactions:
Expired	(591,485)
Nabi \| Post Merger
Balance Outstanding	508,918
Post-merger transactions:
Expired		(16,979)
Nabi
Balance Outstanding		491,939	3,665,201
Post-merger transactions:
Exercisable at March 31, 2013		491,939
Adjustment for consolidation of shares (reverse stock split)	(2,544,716)
Forfeited	(20,000)
Post Merger
Post-merger transactions:
Granted		931,590
Balance Outstanding		931,590

Note 5 - Share Based Compensation (Detail) - Summary of Restricted Stock Awards - shares	4 Months Ended	5 Months Ended
	Nov. 08, 2012	Mar. 31, 2013	Jun. 30, 2012
Nabi
Unvested at June 30, 2012			196,254
Vested	(196,254)
Post-merger transactions:
Outstanding at March 31, 2013
Biota
Vested		(71,661)
Post-merger transactions:
Granted		214,983
Outstanding at March 31, 2013		143,322

Note 6 - Research and Development Credit (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012	Jun. 30, 2012
Research and Development Credit	$ 0	$ 0	$ 4,428	$ 0	$ 4,400

Note 7 - Licences, Royalty Collaborative and Contractual Arrangements (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		24 Months Ended
	Mar. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Major Countries \| GSK
Royalty Payment Percentage					7.00%
Australia, New Zealand, South Africa and Indonesia \| GSK
Royalty Payment Percentage					10.00%
Daiichi Sankyo
Royalty Payment Percentage					4.00%
BARDA
Contracts Revenue (in Dollars)							$ 22.5
Contract Term				5 years
Contracts Revenue (in Dollars)	$ 231.2	$ 0.2	$ 0.1		$ 1.0	$ 0.4

Note 7 - Licences, Royalty Collaborative and Contractual Arrangements (Detail) - Components of Revenues from Royalties, Collaborative and Contractual Agreements - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2011	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012	Jun. 30, 2011
Relenza [Member]
Royalty Revenue		$ 1,700	$ 1,700	$ 2,700	$ 2,400
Inavir [Member]
Royalty Revenue		3,200	3,600	4,100	4,300
Commercial milestone – Inavir®		2,900		2,900
BARDA
Service revenue under BARDA contract		4,500	1,700	13,700	6,200
Revenue under other contracts, grants and collaborations						$ 231,000
Royalty Revenue		7,709	5,189	9,636	6,649
Revenue under other contracts, grants and collaborations	$ 231,200	200	100	1,000	400
Total revenue		$ 12,496	$ 7,090	$ 24,346	$ 13,329

Note 8 - Subsequent Events (Detail) - USD ($) $ in Millions		3 Months Ended
Note 8 - Subsequent Events (Detail) - USD ($) $ in Millions	May 02, 2013	Mar. 31, 2013	Apr. 15, 2013
Subsequent Event [Member]
Percentage of Workforce Reduced			30.00%
Treasury Stock, Shares, Retired (in Shares)	5,867,361
Anticipated Charges [Member]
Severance Costs (in Dollars)		$ 2.0

- Definition

The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5-8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 8-13, 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS146-1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 112
-Paragraph 7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details